JAZZ
Jazz Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 28, 5:30 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) is down 7% after hours on light volume on the heels of the company's announcement that enrollment is now complete in its 240-subject Phase 3 clinical trial assessing JZP-110 for the treatment of excessive sleepiness (ES) associated with narcolepsy. Top-line data are expected in Q2 2017.
    • Top-line results in another Phase 3 assessing JZP-110 for the treatment of ES in obstructive sleep apnea should be available in Q1 2017.
    • JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor. It has Orphan Drug status in the U.S. for narcolepsy.
    | Mon, Nov. 28, 5:30 PM | 6 Comments
  • Tue, Nov. 8, 5:40 PM
    | Tue, Nov. 8, 5:40 PM
  • Tue, Nov. 8, 4:19 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q3 EPS of $2.57 misses by $0.04.
    • Revenue of $374.2M (+9.8% Y/Y) misses by $15.03M.
    • Shares -2.7%.
    • Press Release
    | Tue, Nov. 8, 4:19 PM
  • Mon, Nov. 7, 5:35 PM
  • Mon, Oct. 3, 9:47 AM
    • Jazz Pharmaceuticals (JAZZ) commences the rolling submission of its New Drug Application (NDA) to the FDA seeking approval of Vyxeos (cytarabine and daunorubicin liposome injection) for the treatment of acute myeloid leukemia (AML), a Breakthrough Therapy-designated indication. The company expects to complete the filing in early 2017.
    • Jazz obtained the rights to Vyxeos via its July acquisition of Celator Pharmaceuticals.
    • Vyxeos, based on the company's CombiPlex platform, is an optimized 5:1 formulation of the commonly used chemo agents cytarabine and daunorubicin.
    | Mon, Oct. 3, 9:47 AM | 2 Comments
  • Mon, Sep. 26, 4:57 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) hits its enrollment target of ~654 subjects in its two Phase 3 clinical trials assessing JZP-110 for the treatment of excessive sleepiness associated with obstructive sleep apnea (OSA). The co-primary endpoints in both studies are the change in mean sleep latency time as measured by the Maintenance of Wakefulness Test and the change in a metric called Epworth Sleepiness Scale. Both endpoints, assessed over a six-week period, measure the severity of excessive sleepiness and the ability to stay awake.
    • Preliminary results should be available in Q1 2017.
    • JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor.
    | Mon, Sep. 26, 4:57 PM
  • Fri, Aug. 26, 7:15 AM
    • Actinium Pharmaceuticals (NYSEMKT:ATNM) initiated with Buy rating and $5 (194% upside) price target by Roth Capital.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Neutral rating by Janney Montgomery Scott.
    • Cantel Medical (NYSE:CMN) initiated with Hold rating by Needham.
    • Patheon NV (Pending:PTHN) initiated with Outperform rating by William Blair.
    • Caladrius Biosciences (NASDAQ:CLBS) initiated with Buy rating and $6.50 (31% upside) price target by Chardan Capital.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) initiated with Buy rating and $5 (92% upside) price target by Rodman & Renshaw.
    • Rockwell Medical (NASDAQ:RMTI) initiated with Buy rating and $12 (72% upside) price target by BTIG Research.
    • Agios Pharmaceuticals (NASDAQ:AGIO) initiated with Neutral rating by BTIG Research.
    • TRACON Pharmaceuticals (NASDAQ:TCON) initiated with Buy rating and $15 (137% upside) price target by BTIG Research.
    • Ophthotech (NASDAQ:OPHT) initiated with Buy rating and $92 (76% upside) price target by BTIG Research.
    • Merrimack Pharmaceuticals (NASDAQ:MACK) initiated with Neutral rating by BTIG Research.
    • Acceleron Pharma (NASDAQ:XLRN) initiated with Buy rating and $46 (55% upside) price target by BTIG Research.
    | Fri, Aug. 26, 7:15 AM | 15 Comments
  • Tue, Aug. 9, 4:10 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q2 EPS of $2.63 misses by $0.17.
    • Revenue of $381.2M (+14.2% Y/Y) beats by $4.78M.
    • Shares -3.3%.
    • Press Release
    | Tue, Aug. 9, 4:10 PM
  • Mon, Aug. 8, 5:35 PM
  • Tue, Jul. 19, 10:50 AM
    • Prompted by moderating growth from traditional drug sales, large cap drug/biotech firms have their sights set on developers of cancer therapies, in particular immunotherapies, to boost both their top and bottom lines. Roche (OTCQX:RHHBY -1.5%), Amgen (AMGN +0.1%), Sanofi (SNY -1.3%) and Gilead Sciences (GILD -1.2%) are all actively on the prowl for acquisitions.
    • Medivation (MDVN +0.1%), with its prostate cancer drug Xtandi (enzalutamide), is currently in play. Sanofi has been the most aggressive with two unsuccessful bids, but Pfizer (PFE) and Celgene (CELG -0.6%) are supposedly interested.
    • Analysts say Incyte (INCY -0.4%), with polycythemia vera and myelofibrosis drug Jakafi (ruxolitinib), and Seattle Genetics (SGEN -0.8%), with lymphoma drug Adcetris (brentuximab vedotin), are the most attractive takeover targets.
    • Recent transactions include AbbVie's (ABBV -0.3%) buyout of Stemcentryx, Jazz Pharmaceuticals' (JAZZ -0.8%) takeout of Celator Pharmaceuticals and Bristol-Myers Squibb's (BMY -0.2%) acquisition of Cormorant Pharmaceuticals.
    | Tue, Jul. 19, 10:50 AM | 8 Comments
  • Tue, Jul. 12, 7:22 AM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) announces the results of its tender offer to purchase all of the outstanding shares of common stock of Celator Pharmaceuticals (NASDAQ:CPXX) at $30.25 per share. The tender offer is being effected by Jazz Pharmaceuticals' indirect wholly-owned subsidiary, Plex Merger Sub.
    • A total of 36.5M shares of Celator common stock had been validly tendered, representing ~81.13% of its outstanding shares. Additionally Notices of Guaranteed Delivery have been delivered with respect to 2M additional shares, representing another 4.48%.
    • In late May, Jazz announced its intent to acquire Celator for $1.5B.
    | Tue, Jul. 12, 7:22 AM
  • Fri, Jul. 1, 10:08 AM
    • Invitae (NYSE:NVTA) initiated with Hold rating with an $8.50 (18% upside) price target by Benchmark.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Outperform rating and $190 (33% upside) price target by BMO.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Underperform rating and $36 (4% upside) price target by BMO.
    • Mallinckrodt (NYSE:MNK) initiated with Outperform rating and $84 (35% upside) price target by BMO.
    • Horizon Pharma plc (NASDAQ:HZNP) initiated with Outperform rating and $29 (71% upside) price target by BMO.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) initiated with an Outperform rating and $400 (13% upside) price target by Bernstein.
    • Biogen (NASDAQ:BIIB) initiated with an Outperform rating and $282 (15% upside) price target by Bernstein.
    • Amgen (NASDAQ:AMGN) initiated with Market Perform rating and $161 (5% upside) price target by Bernstein.
    • Lannett Company (NYSE:LCI) initiated with Hold rating and $26 (5% upside) price target by Deutsche Bank.
    • OpGen (NASDAQ:OPGN) initiated with Buy rating and $2.50 (66% upside) price target by Rodman & Renshaw.
    • Valeant Pharmaceuticals (NYSE:VRX) initiated with Market Perform rating and $26 (22% upside) price target by BMO.
    • Neurocrine Biosciences (NASDAQ:NBIX) initiated with Outperform rating and $80 (75% upside) price target by H.C. Wainwright.
    • Healthstream (NASDAQ:HSTM) initiated with Outperform rating and $30 (12% upside) price target by Barrington Research.
    • Neurometrix (NASDAQ:NURO) initiated with Buy rating and $4.50 (165% upside) price target by Rodman & Renshaw.
    • Vascular Biogenics (NASDAQ:VBLT) initiated with Buy rating and $11 (139% upside) price target by H.C. Wainwright.
    | Fri, Jul. 1, 10:08 AM | 7 Comments
  • Wed, Jun. 15, 5:32 PM
    | Wed, Jun. 15, 5:32 PM | 13 Comments
  • Tue, Jun. 14, 4:37 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) will host a conference call and audio webcast on June 20 at 4:30 pm ET to update investors on JZP-110, its Phase 3-stage wake-promoting agent under development for the treatment of excessive sleepiness in adults with narcolepsy or obstructive sleep apnea.
    • Jazz acquired the rights to the drug from Aerial BioPharma in early 2014.
    | Tue, Jun. 14, 4:37 PM | 1 Comment
  • Fri, Jun. 10, 7:19 AM
    • Boston Scientific (NYSE:BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
    • Zimmer Biomet Holdings (NYSE:ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
    • Edwards Lifesciences (NYSE:EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
    • Oncobiologics (Pending:ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
    • Walgreens Boots Alliance (NASDAQ:WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
    • Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ:JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ:HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ:ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE:MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ:MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ:CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ:IPXL) - $33 (2% downside risk) price target.
    • Biocept (NASDAQ:BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
    • Seres Therapeutics (NASDAQ:MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
    • Omeros (NASDAQ:OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
    • Glaukos (NYSE:GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
    • Shire plc (NASDAQ:SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.
    | Fri, Jun. 10, 7:19 AM
  • Tue, May 31, 3:49 AM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) is nearing a deal to buy Celator (NASDAQ:CPXX) for $1.5B, or about double its market cap - a huge premium even in biotechnology, where acquirers often pay for promising new drugs.
    • About three months ago, Celator said its Vyxeos treatment helped older high-risk patients with a deadly form of leukemia live longer than those who received the standard of care regimen, sending its stock price soaring.
    • CPXX +78.3% premarket
    • Update: Jazz announces that it will acquire Celator for $30.25 per share in cash or ~$1.5B.
    | Tue, May 31, 3:49 AM | 16 Comments